X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (38) 38
index medicus (37) 37
humans (35) 35
female (26) 26
middle aged (25) 25
male (24) 24
aged (21) 21
adult (20) 20
cancer (18) 18
pharmacology & pharmacy (18) 18
patients (13) 13
tumors (13) 13
neoplasms - drug therapy (12) 12
renal-cell carcinoma (12) 12
analysis (10) 10
dose-response relationship, drug (10) 10
drug dosages (10) 10
medicine & public health (10) 10
care and treatment (9) 9
metastasis (9) 9
pazopanib (9) 9
pharmacokinetics (9) 9
protein kinase inhibitors - pharmacokinetics (9) 9
antineoplastic agents - pharmacokinetics (8) 8
antineoplastic agents - therapeutic use (8) 8
feasibility studies (8) 8
pharmacology (8) 8
pharmacology/toxicology (8) 8
therapeutic drug monitoring (8) 8
young adult (8) 8
aged, 80 and over (7) 7
chronic myeloid-leukemia (7) 7
imatinib (7) 7
phase-i (7) 7
protein kinase inhibitors - administration & dosage (7) 7
protein kinase inhibitors - adverse effects (7) 7
protein kinase inhibitors - therapeutic use (7) 7
sunitinib (7) 7
antineoplastic agents - adverse effects (6) 6
cancer therapies (6) 6
drug therapy (6) 6
exposure (6) 6
mutation (6) 6
plasma (6) 6
research (6) 6
retrospective studies (6) 6
sarcoma (6) 6
studies (6) 6
treatment outcome (6) 6
trial (6) 6
angiogenesis inhibitors - administration & dosage (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
breast-cancer (5) 5
dosage and administration (5) 5
endothelial growth-factor (5) 5
gastrointestinal stromal tumors - drug therapy (5) 5
gist (5) 5
internal medicine (5) 5
pharmacotherapy (5) 5
population pharmacokinetics (5) 5
risk factors (5) 5
toxicity (5) 5
tyrosine kinase inhibitors (5) 5
angiogenesis inhibitors - pharmacokinetics (4) 4
antineoplastic agents - administration & dosage (4) 4
antitumor-activity (4) 4
biomarkers (4) 4
biopsy (4) 4
clinical study (4) 4
drug monitoring - methods (4) 4
efficacy (4) 4
erlotinib (4) 4
health aspects (4) 4
hypertension (4) 4
imatinib mesylate (4) 4
imatinib mesylate - therapeutic use (4) 4
indoles - pharmacokinetics (4) 4
maximum tolerated dose (4) 4
metastases (4) 4
neoplasms - enzymology (4) 4
neoplasms - genetics (4) 4
original (4) 4
pharmacogenetics (4) 4
protein-tyrosine kinases - antagonists & inhibitors (4) 4
pyrimidines - administration & dosage (4) 4
pyrimidines - pharmacokinetics (4) 4
pyrroles - pharmacokinetics (4) 4
soft tissue sarcoma (4) 4
solid tumors (4) 4
sulfonamides - administration & dosage (4) 4
survival (4) 4
time factors (4) 4
tyrosine kinase inhibitor (4) 4
adolescent (3) 3
advanced cancer (3) 3
advanced solid tumors (3) 3
angiogenesis (3) 3
angiogenesis inhibitor (3) 3
angiogenesis inhibitors - adverse effects (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 3117 - 3117
Journal Article
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 3/2017, Volume 56, Issue 3, pp. 287 - 292
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2016, Volume 11, Issue 2, pp. e0149405 - e0149405
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 3119 - 3119
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 05/2018, Volume 57, Issue 5, pp. 637 - 644
Background The mammalian target of rapamycin (mTOR) inhibitor everolimus is used in the treatment of breast cancer, neuroendocrine tumors, and renal cancer.... 
BREAST-CANCER | METAANALYSIS | BOLERO-2 | EFFICACY | PHARMACOLOGY & PHARMACY | TUMORS | RENAL-CELL CARCINOMA | EXPOSURE | Survival analysis | Transplants & implants | Feasibility studies | Oncology | Breast cancer | Patients | Drug dosages | Tumors | Original
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 318 - 325
Although gastrointestinal stromal tumours (GIST) predominantly occur in older patients, data on treatment patterns in elderly GIST patients are scarce.... 
GIST | Imatinib | Elderly | Gastrointestinal stromal tumours | ONCOLOGY | PROGNOSIS | AGE | Multivariate Analysis | Age Factors | Gastrointestinal Neoplasms - mortality | Gastrointestinal Stromal Tumors - secondary | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Practice Patterns, Physicians | Young Adult | Gastrointestinal Neoplasms - pathology | Netherlands | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Registries | Retrospective Studies | Chemotherapy, Adjuvant | Gastrointestinal Stromal Tumors - mortality | Odds Ratio | Comorbidity | Risk Factors | Kaplan-Meier Estimate | Logistic Models | Treatment Outcome | Digestive System Surgical Procedures - adverse effects | Gastrointestinal Neoplasms - therapy | Chi-Square Distribution | Disease Progression | Disease-Free Survival | Process Assessment (Health Care) | Gastrointestinal Stromal Tumors - therapy | Delivery of Health Care | Adolescent | Healthcare Disparities | Aged | Health Status | Digestive System Surgical Procedures - mortality | Aged patients | Care and treatment | Analysis | Tumors | Elderly people | Toxicity | Complications | Medical treatment | Regression analysis | Patients | Survival | Metastases | Studies | Older people | Gastrointestinal diseases | Surgery | Geriatrics | Index Medicus
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 5/2019, Volume 58, Issue 5, pp. 651 - 658
As pazopanib plasma trough concentrations are correlated with treatment outcome, we explored whether single nucleotide polymorphisms in the elimination pathway... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | ALLELE | T POLYMORPHISM CYP3A4-ASTERISK-22 | GENOTYPE | SAFETY | GENES | PHARMACOLOGY & PHARMACY | PHASE-I | VARIANT | RENAL-CELL CARCINOMA | EXPOSURE | Cytochrome | Studies | Enzymes | Transplants & implants | Leukemia | Kidney cancer | Metabolism | Drug dosages | Polymorphism | Original
Journal Article
Anticancer Research, ISSN 0250-7005, 03/2019, Volume 39, Issue 3, pp. 1309 - 1316
Journal Article
Therapeutic Drug Monitoring, ISSN 0163-4356, 2014, Volume 36, Issue 3, pp. 326 - 334
BACKGROUND: The objectives of this study were to evaluate the plasma concentrations of the tyrosine kinase inhibitors (TKIs), imatinib, erlotinib, and... 
Therapeutic drug monitoring | tyrosine kinase inhibitors | unselected patient cohort | trough plasma levels | RESISTANCE PROTEIN | TANDEM MASS-SPECTROMETRY | ANTITUMOR-ACTIVITY | SU11248 | CHRONIC MYELOID-LEUKEMIA | BREAST-CANCER | POPULATION PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | GROWTH-FACTOR | MEDICAL LABORATORY TECHNOLOGY | GASTROINTESTINAL STROMAL TUMORS | PHASE-I | therapeutic drug monitoring | Erlotinib Hydrochloride | Proton Pump Inhibitors - pharmacology | Body Weight | Pyrroles - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Gastric Acid - chemistry | Benzamides - pharmacokinetics | Humans | Middle Aged | Half-Life | Quinazolines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Chromatography, High Pressure Liquid | Drug Monitoring - methods | Dose-Response Relationship, Drug | Tandem Mass Spectrometry | Benzamides - therapeutic use | Female | Antineoplastic Agents - pharmacokinetics | Piperazines - pharmacokinetics | Pyrroles - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Piperazines - therapeutic use | Histamine H2 Antagonists | Imatinib Mesylate | Neoplasms - drug therapy | Outpatients | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Pyrimidines - pharmacokinetics | Indoles - pharmacokinetics | Indoles - therapeutic use | Aged | Plasma | Pharmacology | Kinases | Outpatient care facilities | Cancer | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 226 - 232
Imatinib 400 mg per day is first-line therapy for patients with gastrointestinal stromal tumours (GISTs). Although clinical benefit is high, progression-free... 
SNPs | GIST | Imatinib | Pharmacogenetic pathway analysis | Survival | VEGF | FOLLOW-UP | OF-FUNCTION MUTATIONS | CANCER | CHRONIC MYELOID-LEUKEMIA | CLINICAL-PRACTICE GUIDELINES | THERAPY | ONCOLOGY | KIT | RESISTANCE | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Angiogenic Proteins - genetics | Multivariate Analysis | Gastrointestinal Neoplasms - genetics | Exons | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Gastrointestinal Stromal Tumors - secondary | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Imatinib Mesylate - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - genetics | Vascular Endothelial Growth Factor Receptor-2 - genetics | Gastrointestinal Neoplasms - pathology | Imatinib Mesylate - therapeutic use | Time Factors | Antineoplastic Agents - adverse effects | Imatinib Mesylate - adverse effects | Pharmacogenomic Variants | Female | Proto-Oncogene Proteins c-kit - genetics | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Gastrointestinal Stromal Tumors - mortality | Gastrointestinal Stromal Tumors - genetics | Protein Kinase Inhibitors - pharmacokinetics | Pharmacogenetics | Genetic Association Studies | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease Progression | Disease-Free Survival | Gastrointestinal Stromal Tumors - drug therapy | Protein Kinase Inhibitors - therapeutic use | Biomarkers, Tumor - genetics | Polymorphism, Single Nucleotide | Mutation | Solute Carrier Organic Anion Transporter Family Member 1B3 - genetics | Antimitotic agents | Care and treatment | Endothelial growth factors | Analysis | Genes | Patient outcomes | Genetic research | Development and progression | Genetic aspects | Single nucleotide polymorphisms | Metastasis | Antineoplastic agents | Therapy | Pharmacodynamics | Digestive system | Health risks | Pharmacology | Single-nucleotide polymorphism | Patients | Metastases | Genotype & phenotype | Angiogenesis | Biomarkers | Genetics | Bioindicators | Pharmacokinetics | Genotypes | Polymorphism | Tumors | Index Medicus
Journal Article